CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling
© 2021. The Author(s), under exclusive licence to Springer Nature Limited..
The YAP/TAZ transcriptional programme is not only a well-established driver of cancer progression and metastasis but also an important stimulator of tissue regeneration. Here we identified Cerebral cavernous malformations 3 (CCM3) as a regulator of mechanical cue-driven YAP/TAZ signalling, controlling both tumour progression and stem cell differentiation. We demonstrate that CCM3 localizes to focal adhesion sites in cancer-associated fibroblasts, where it regulates mechanotransduction and YAP/TAZ activation. Mechanistically, CCM3 and focal adhesion kinase (FAK) mutually compete for binding to paxillin to fine-tune FAK/Src/paxillin-driven mechanotransduction and YAP/TAZ activation. In mouse models of breast cancer, specific loss of CCM3 in cancer-associated fibroblasts leads to exacerbated tissue remodelling and force transmission to the matrix, resulting in reciprocal YAP/TAZ activation in the neighbouring tumour cells and dissemination of metastasis to distant organs. Similarly, CCM3 regulates the differentiation of mesenchymal stromal/stem cells. In conclusion, CCM3 is a gatekeeper in focal adhesions that controls mechanotransduction and YAP/TAZ signalling.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
Nature cell biology - 23(2021), 7 vom: 05. Juli, Seite 758-770 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Shan [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 20.09.2021 Date Revised 04.02.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41556-021-00702-0 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM327731958 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM327731958 | ||
003 | DE-627 | ||
005 | 20231225201432.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41556-021-00702-0 |2 doi | |
028 | 5 | 2 | |a pubmed24n1092.xml |
035 | |a (DE-627)NLM327731958 | ||
035 | |a (NLM)34226698 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wang, Shan |e verfasserin |4 aut | |
245 | 1 | 0 | |a CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 20.09.2021 | ||
500 | |a Date Revised 04.02.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Author(s), under exclusive licence to Springer Nature Limited. | ||
520 | |a The YAP/TAZ transcriptional programme is not only a well-established driver of cancer progression and metastasis but also an important stimulator of tissue regeneration. Here we identified Cerebral cavernous malformations 3 (CCM3) as a regulator of mechanical cue-driven YAP/TAZ signalling, controlling both tumour progression and stem cell differentiation. We demonstrate that CCM3 localizes to focal adhesion sites in cancer-associated fibroblasts, where it regulates mechanotransduction and YAP/TAZ activation. Mechanistically, CCM3 and focal adhesion kinase (FAK) mutually compete for binding to paxillin to fine-tune FAK/Src/paxillin-driven mechanotransduction and YAP/TAZ activation. In mouse models of breast cancer, specific loss of CCM3 in cancer-associated fibroblasts leads to exacerbated tissue remodelling and force transmission to the matrix, resulting in reciprocal YAP/TAZ activation in the neighbouring tumour cells and dissemination of metastasis to distant organs. Similarly, CCM3 regulates the differentiation of mesenchymal stromal/stem cells. In conclusion, CCM3 is a gatekeeper in focal adhesions that controls mechanotransduction and YAP/TAZ signalling | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Adaptor Proteins, Signal Transducing |2 NLM | |
650 | 7 | |a Apoptosis Regulatory Proteins |2 NLM | |
650 | 7 | |a Intracellular Signaling Peptides and Proteins |2 NLM | |
650 | 7 | |a Membrane Proteins |2 NLM | |
650 | 7 | |a PDCD10 protein, human |2 NLM | |
650 | 7 | |a PDCD10 protein, mouse |2 NLM | |
650 | 7 | |a PXN protein, human |2 NLM | |
650 | 7 | |a Paxillin |2 NLM | |
650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
650 | 7 | |a Pxn protein, mouse |2 NLM | |
650 | 7 | |a Transcription Factors |2 NLM | |
650 | 7 | |a Transcriptional Coactivator with PDZ-Binding Motif Proteins |2 NLM | |
650 | 7 | |a WWTR1 protein, human |2 NLM | |
650 | 7 | |a Wwtr1 protein, mouse |2 NLM | |
650 | 7 | |a YAP-Signaling Proteins |2 NLM | |
650 | 7 | |a YAP1 protein, human |2 NLM | |
650 | 7 | |a Yap1 protein, mouse |2 NLM | |
650 | 7 | |a Focal Adhesion Kinase 1 |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
650 | 7 | |a PTK2 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
650 | 7 | |a Ptk2 protein, mouse |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
650 | 7 | |a src-Family Kinases |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
700 | 1 | |a Englund, Emelie |e verfasserin |4 aut | |
700 | 1 | |a Kjellman, Pontus |e verfasserin |4 aut | |
700 | 1 | |a Li, Zhen |e verfasserin |4 aut | |
700 | 1 | |a Ahnlide, Johannes Kumra |e verfasserin |4 aut | |
700 | 1 | |a Rodriguez-Cupello, Carmen |e verfasserin |4 aut | |
700 | 1 | |a Saggioro, Mattia |e verfasserin |4 aut | |
700 | 1 | |a Kanzaki, Ryu |e verfasserin |4 aut | |
700 | 1 | |a Pietras, Kristian |e verfasserin |4 aut | |
700 | 1 | |a Lindgren, David |e verfasserin |4 aut | |
700 | 1 | |a Axelson, Håkan |e verfasserin |4 aut | |
700 | 1 | |a Prinz, Christelle N |e verfasserin |4 aut | |
700 | 1 | |a Swaminathan, Vinay |e verfasserin |4 aut | |
700 | 1 | |a Madsen, Chris D |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature cell biology |d 1999 |g 23(2021), 7 vom: 05. Juli, Seite 758-770 |w (DE-627)NLM104898879 |x 1476-4679 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2021 |g number:7 |g day:05 |g month:07 |g pages:758-770 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41556-021-00702-0 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2021 |e 7 |b 05 |c 07 |h 758-770 |